SubscribeLatest 5 articles from heartwire
- Sen Grassley questions top medical schools about ghostwriting
Nov 20, 2009 13:15 EDT - Stroke incidence related to PCI steady over 15 years
Nov 20, 2009 13:00 EDT - ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment
Nov 19, 2009 14:00 EDT - Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI
Nov 19, 2009 11:00 EDT - EFFECT: Public reporting of hospital performance improves quality of care?
Nov 19, 2009 10:00 EDT
Episode #16: PLATO, ticagrelor, and platelet inhibition: Insight from Lars Wallentin
Please note that the audio will stop and restart at the beginning of the file when submitting a comment.
Veuillez notez que le fichier audio s’arrête et recommence au début lorsqu’un commentaire est publié.
DOWNLOAD
Download this episode in your preferred format:
- An explanation of why ticagrelor is a different type of platelet inhibitor
- Top line results of PLATO
- Insight into the mortality finding
- A review of the invasively managed cohort data presented by Chris Cannon at TCT 2009
- Discussion of the effect on stent thrombosis The "North American issue" and what might explain the anomalous North American results compared to those of the rest of the world
- Background on the late-breaker—addresssing patients with STEMI—at AHA 2009 that will be presented by Gabriel Steg
What are your thoughts? Join in by commenting below.
Previous postsBillets précédents
Also from theheart.org
About The Bob Harrington Show
Take part in this new interactive series! Start by joining Dr Harrington and his guests for a frank and insightful review of the latest clinical trials, events and education in the realm of cardiology. Then it’s your turn: share your thoughts by writing them in the comments box (at left) or by phoning our studios and leaving a voice message: 1-866-996-5440. There’s a show posted every two weeks, why not join in? We value the diverse opinions of our readership — that includes you — and look forward to a hearty exchange!
About Dr Robert A Harrington
Dr Robert A Harrington is a Professor of Medicine at Duke University, Director of the Duke Clinical Research Institute, and a practicing interventional cardiologist. He is the recipient of an NIH Roadmap contract to investigate “best practices” among clinical trial networks, and is a Fellow of the ACC, AHA, SCAI, and American College of Chest Physicians. In addition, he currently serves as a member of the FDA Cardiovascular and Renal Drugs Advisory Committee and is a member of the NHLBI’s study section for clinical trials. A member of the ACC’s Board of Trustees, Dr Harrington chaired the ACC 2006 Annual Scientific Sessions.
CommentsCommentaires